Claim Missing Document
Check
Articles

Found 29 Documents
Search

Antigenic differences between wildtype measles viruses and vaccine viruses in Indonesia Made Setiawan; Agus Sjahrurachman; Fera Ibrahim; Agus Suwandono
Paediatrica Indonesiana Vol 48 No 3 (2008): May 2008
Publisher : Indonesian Pediatric Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (245.696 KB) | DOI: 10.14238/pi48.3.2008.125-35

Abstract

Background Measles virus has a single, negative strand RNAgenome which codes 6 structural proteins: N, F, P M, H and L.Currently there are several variances in the nucleotide sequencesof N, F, M and H genes across wild type measles viruses, hencemeasles viruses can be categorized into clades and genotypes. Theantigenicity of the previous genotype of measles is different fromthe current genotype.Objective To determine the antigenic differences between wildtype measles virus and measles vaccine virus.Methods Analysis of the antigenic differences between wild typevirus (G2, G3 and D9) and vaccine virus (CAM-70 and Schwarz)was performed by immunizing mice with the respective viruses.The serum was then tested with micro-cross-neutralizationtechnique using the G2, G3, D9 and CAM-70 virus. Tests withcross ELISA examination technique were also performed usingthe same set of virus.Results Analysis of the cross neutralization test and cross ELISAshowed that the highest antigenicity reaction was found betweenwild type virus with antibody against wild type virus, while thelowest reaction was between wild type virus with antibody againstCAM-70.Conclusions We conclude that the antigenicity of antigenic proteinfrom wild type virus is higher than antigenicity of vaccine virusprotein. In addition, it was found that the antigenicity of proteinsfrom Schwarz vaccine virus was higher than proteins CAM-70vaccine virus.
Level of Retinol Deposit and Cervical Cancer Tofan W Utami; Fera Ibrahim; Gatot Purwoto; Wely L Tiffani; Muhammad F Aziz; Andrijono Andrijono
Indonesian Journal of Obstetrics and Gynecology Volume. 5, No. 1, January 2017
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (131.483 KB) | DOI: 10.32771/inajog.v5i1.465

Abstract

Objective: To analyze level of retinol deposit sufficiency in the natural history of cervical cancer. Methods: Serum retinol level was measured by ELISA from peripheral blood of subjects with normal cervix, cleared and persistent high risk human papilloma virus (HR-HPV) subclinical infection, and cervical cancer who fulfilled the inclusion and exclusion criteria. The study was held in Dr. Cipto Mangunkusumo and Fatmawati Hospital, Jakarta, within 2 years (August 2013- 2015). Blood was taken twice, consisting of post-8-hour fasting blood and 2 hours after 6000 IU retinyl palmitate oral administration. Results: Of 47 total samples, sufficient level of retinol deposit in normal cervix, cleared and persistent HR-HPV subclinical infection, and cervical cancer group was 85.0% (reference), 75.0% (OR 1.89), 33.3% (OR 11.33), and 75% (OR 1.89); respectively. Statistically, there was no significant difference from sufficiency level of retinol deposit between normal cervix and clearance HR-HPV subclinical infection (p=0.628), normal cervix and persistent HR-HPV subclinical infection (p=0.078), normal cervix and cervical cancer (p=0.433), cervical cancer and clearance HR-HPV subclinical infection (p=1.000), cervical cancer and persistent HR-HPV subclinical infection (p=0.430), persistent and clearance HR-HPV subclinical infection group (p=0.740). Conclusion: This study proves that normal cervix group has the highest level of retinol deposit sufficiency; however, it cannot be stated that cervical cancer group has less sufficiency level. Persistent HR-HPV subclinical infection group has the lowest level of retinol deposit (OR 11.33). There is no association between sufficient level of retinol deposit and clearance of HR-HPV. [Indones J Obstet Gynecol 2017; 5-1: 46-54] Keywords: cervical cancer, HR-HPV clearance, retinol deposit
Deteksi Acinetobacter baumannii Multiresisten Obat Penghasil Biofilm menggunakan Pewarnaan Berbasis Crystal Violet Ardiana Kusumaningrum; Iin Maemunah; Dimas Seto Prasetyo; Fera Ibrahim; Budiman Bela
The Indonesian Journal of Infectious Diseases Vol 5, No 2 (2019): The Indonesian Journal of Infectious Disease
Publisher : Rumah Sakit Penyakit Infeksi Prof Dr. Sulianti Saroso

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (120.703 KB) | DOI: 10.32667/ijid.v5i2.86

Abstract

Pendahuluan: Kasus infeksi terkait biofilm merupakan masalah besar pada dunia kesehatan karena sifat kekebalannya terhadap antibiotik dan respon imun, terutama pada kasus infeksi kronik akibat Acinetobacter baumannii. Saat ini terdapat berbagai metode deteksi pembentukan biofilm, namun pemeriksaan tersebut belum dilakukan secara rutin karena berbagai keterbatasan. Oleh karena itu, perlu dilakukan optimasi metode deteksi biofilm menggunakan bahan yang rutin tersedia di laboratorium serta mengukur proporsi sampel yang mengandung bakteri penghasil biofilm Metode: Desain penelitian ini adalah uji eksperimental. Pada penelitian ini dilakukan pengembangan deteksi pembentukan biofilm menggunakan metoda tabung microcentrifuse tube 1,5 ml berbahan polypropylene dengan zat warna berbasis crystal violet konsentrasi 0,1% dan 1%. Optimasi yang dilakukan meliputi media biakan, lama inkubasi, inokulum bakteri yang digunakan serta bahan pembilas. Isolat bakteri Pseudomonas aeruginosa ATCC 10145, A. baumannii ATCC 19606  dan Staphylococcus aureus ATCC 25923 digunakan sebagai kontrol positif dan kontrol negatif pemeriksaan yang dilakukan. Hasil: Pemeriksaan optimasi yang dilakukan, diperoleh kondisi optimal pembentukan biofilm menggunakan media Luria Bertani dengan besar inokulum 1 sengkelit penuh, lama inkubasi 30 jam dan pewarnaan dilakukan menggunakan crystal violet 0,1% serta bahan pembilas berupa PBS steril. Proporsi pembentukan biofilm pada A. baumannii multiresisten obat sebesar 55,3%. Kesimpulan: Metode deteksi pembentukan biofilm menggunakan metode tabung polypropylene yang dimodifikasi dan pewarnaan zat warna crystal violet 0,1% merupakan metode deteksi yang mudah dikerjakan, reproducible dan efisien, sehingga dapat dilakukan di laboratorium mikrobiologi klinik sederhana. Proporsi bakteri penghasil biofilm adalah lebih dari 50% A. baumannii resisten multiobat.
A comparison study of GeneXpert and In-House N1N2 CDC Real-Time RT-PCR for detection of SARS-CoV-2 infection Andi Yasmon; Lola Febriana Dewi; Fithriyah Fithriyah; Ariyani Kiranasari; Andriansjah Rukmana; Yulia Rosa Saharman; Fera Ibrahim; Pratiwi Sudarmono
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 54, No 3 (2022)
Publisher : Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19106/JMedSci005403202203

Abstract

COVID-19 is a disease caused by SARS-CoV-2, a new virus from genus β-coronaviruses. This disease has been declared a pandemic by WHO on 11 March 2020 until now. The nucleic acid tests are the most frequently used assays because of their high sensitivity and specificity. One of the tests is the GeneXpert, a real-time reverse transcription polymerase chain reaction (rRT-PCR)-based assay platform. The use of the GeneXpert shows great public health interest because of the rapid (50 min), the minimum number of trained staff, and less infrastructure and equipment. However, there are limited data on the application of the GeneXpert for the detection of SARS-CoV-2. Therefore, we conducted a comparative study between the GeneXpert and in-house N1N2 CDC rRT-PCR assay. Of 86 samples, 17 were rRT-PCR positive while 13 were GeneXpert positive. Of rRT-PCR positive 17 samples, 7 were GeneXpert negative [58.82% (10/17] sensitivity]. We also found that 3 GeneXpert positive samples showed rRT-PCR negative (95.65% [66/69] specificity). It is concluded that negative results by the GeneXpert can not rule out the possibility of SARS-CoV-2 infection, particularly in close-contact individuals and the interpretation of the positive result should be analyzed carefully, particularly amplification with Ct>40.
Multidrug Resistance and Extensively Drug-Resistance in Staphylococcus aureus, Staphylococcus epidermidis, and Staphylococcus haemolyticus Cliff Clarence Haliman; Dimas Seto Prasetyo; Conny R Tjampakasari; Fera Ibrahim; T Mirawati Sudiro
Microbiology Indonesia Vol. 16 No. 2 (2022): December
Publisher : Indonesian Society for microbiology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (153.58 KB) | DOI: 10.5454/mi.16.2.15-23

Abstract

Antimicrobial resistance in bacteria has become a leading global public health issue. Staphylococcus sp. has an efficient mechanism to deal with antimicrobial agents that make them hard to treat in hospital-acquired and community-acquired infections. This study was conducted due to limited data about multidrug resistance and extensively drug resistance in Staphylococcus sp. in Indonesia. This study was a descriptive retrospective study using a cross-sectional design to get the prevalence and antimicrobial susceptibility of S. haemolyticus, S. aureus, and S. epidermidis. The data was secondary data extracted from WHONET 2022 software. This study’s data were from bacteria from samples sent to UKK LMK FKUI, Jakarta from 2017 to 2021 for routine diagnostic. In this study, we found that the prevalence of methicillin-resistant S.aureus was 24,9%, methicillin-resistant S.epidermidis was 65,5%, and methicillin-resistant S.haemolyticus was 86,8%. The prevalence of MDR S.aureus is less than S.epidermidis and S.haemolyticus, respectively. MDR S.haemolyticus was consistently above 85% each year, while S.epidermidis was above 50% and S.aureus was below 50%. XDR Staphylococcus was only found in S.aureus and S.haemolyticus, i.e. three and seven XDR isolates of S.aureus and S.haemolyticus respectively during 2017-2021. Although we could not find any pan-resistant isolates from all samples, we found methicillin-resistant S.aureus and S.haemolyticus isolates that were also resistant to vancomycin and linezolid. S.haemolyticus dan S. epidermidis were an important coagulase-negative Staphylococcus species that can’t be neglected due to the high percentage of MDR and the discoveries of XDR in S.haemolyticus so that they have the potential to disseminate resistance plasmids to the more virulent bacteria. Therefore we need to control the use of antimicrobial agent to prevent this resistance.
Limit of Detection (LOD) of in-house N1N2 CDC real-time RT-PCR assay and commercial kits to detect SARS-CoV-2 Simon Yosonegoro Liem; Fera Ibrahim; Andi Yasmon
Journal of Clinical Microbiology and Infectious Diseases Vol. 2 No. 2 (2022): Available Online: December 2022
Publisher : Indonesian Society for Clinical Microbiology (Perhimpunan Dokter Spesialis Mikrobiologi Klinik Indonesia)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/jcmid.v2i2.23

Abstract

Introduction: There are two types of SARS-CoV-2 real-time RT-PCR (rRT-PCR) kits used in the laboratory in Indonesia, in-house and commercial kits. Our laboratory developed an in-house kit based on N1N2 CDC. In this study, we reported the In-house kit's Limit of Detection (LOD) compared with several commercial kits. Method: This report was an experimental study conducted in Clinical Microbiology Laboratory, Microbiology Department, FMUI in Jakarta. Commercial SARS-CoV-2 RNA (Vircell, Granada, Spain, Lot No. 20MBC137004-R) was used. The LoD was determined using a 2-fold dilution of the RNA in DNase/RNase-free water (Vircell®). The diluted RNA(s) were used as templates for in-house and commercial rRT-PCR kits.  Result: The LOD of in-house rRT-PCR and three commercial kits (BioCoV-19 [Bio Farma], Standard M [SD Biosensor], and Real-Q [BioSewoom]) showed higher sensitivity (3.5 copies/reaction) than Power Chek [Kogenebiotech] (7 copies/reaction).  Conclusion: The LOD of our In-house kit showed high performance in sensitivity and comparable with other commercial kit.
TROUBLESHOOTING IN EXPRESSION AND PURIFICATION OF RECOMBINANT SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS NUCLEOCAPSID PROTEIN IN Escherichia coli BL21 Yasmon, Andi; Ibrahim, Fera; Bela, Budiman
Makara Journal of Science Vol. 14, No. 2
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Uji In Vitro Beberapa Kombinasi Antibiotik Antipseudomonas terhadap Pseudomonas aeruginosa yang Resisten terhadap Karbapenem Prasetyo, Dimas Seto; Herna, Herna; Mursinah, Mursinah; Ibrahim, Fera; Bela, Budiman
Jurnal Kefarmasian Indonesia VOLUME 12, NOMOR 1, FEBRUARI 2022
Publisher : Pusat Penelitian dan Pengembangan Biomedis dan Teknologi Dasar Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22435/jki.v0i0.5008

Abstract

Lower respiratory tract, sepsis, or urinary tract infection caused by the multidrug resistance Pseudomonas aeruginosa is common in the hospital, especially in the ICU wards. The treatment against this bacteria requires combination of antibiotics with different mechanism of actions. In this study, several combinations of antibiotics were evaluated in vitro against carbapenem-resistant P. aeruginosa isolated from the ICU of Cipto Mangunkusumo Hospital. The combination of antibiotics tested were ceftazidime-amikacin, ceftazidime-ciprofloxacin, and ciprofloxacin-amikacin. Checkerboard assay to the combination of antibiotics was conducted to assess the in vitro synergistic activity. A total of 22 P. aeruginosa isolates were collected, 16 of them were resistant to ceftazidime, ciprofloxacin, amikacin, as well as carbapenem. The result revealed that the combination of ceftazidime and amikacin showed promising synergistic activity. Conversely, no synergitic activities were shown by the combination of ceftazidime-ciprofloxacin and ciprofloxacin-amikacin. The combination of ceftazidime-amikacin may has potential effect againsts carbapenem-resistant P. aeruginosa in vitro.
Application of Nipah Pseudovirus System for Development of Antibody Neutralization Assay Anna, Shoffiana Noor; Fera Ibrahim
EKSAKTA: Berkala Ilmiah Bidang MIPA Vol. 26 No. 01 (2025): Eksakta : Berkala Ilmiah Bidang MIPA (E-ISSN : 2549-7464)
Publisher : Faculty of Mathematics and Natural Sciences (FMIPA), Universitas Negeri Padang, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24036/eksakta/vol26-iss01/569

Abstract

Nipah virus (NiV) is a type of virus that can make people and many animals very sick.  It can cause serious breathing problems and brains welling.  Because of how dangerous and deadly it is, the World Health Organization (WHO) sees NiV as a global healthrisk.  It needs to be handled in special labs that have the highest safety measures, called Biosafety Level-4 (BSL-4) facilities.  Rightnow, there isn't a good vaccine or treatment available for NiV.  It could be a health risk for Indonesia since it has been found in nearby countries. Indonesia doesn't have a BSL-4 lab yet. So, we need a way to evaluation NiV vaccine that can be done in a BSL-2 lab.  The NiV pseudovirus (PV NiV) has special proteins that help it attach to and enter mammal cells.  It is made using a system based on HIV and includes a signal detector.  This setup can help create tests to measure how well antibodies work against NiV.  It can also be used to monitor infections, check community immunity, develop NiV vaccines, and research new treatments to fight NiV infections.